

ORDERING AND BILLING EXPAREL FOR YOUR FACILITY WITH HCPCS CODE C9290

EXPAREL can be ordered in cartons of 4 or 10...



| NDC # (on package label) | EXPAREL Dose/Vial Size | Configuration |
|-----------------------------|---------------------------|--------------------|
| 65250-133-04 | 133 mg/10 mL | Carton of 4 vials |
| 65250-133-09 | 133 mg/10 mL | Carton of 10 vials |
| 65250-266-04 | 266 mg/20 mL | Carton of 4 vials |
| 65250-266-09 | 266 mg/20 mL | Carton of 10 vials |

...and can be billed as single vials



| NDC # (on package label) | EXPAREL Dose/Vial Size | Configuration | NDC # (for billing)* |
|-----------------------------|---------------------------|------------------|-------------------------|
| 65250-133-10 | 133 mg/10 mL | Single-dose vial | 65250-0133-10 |
| 65250-266-20 | 266 mg/20 mL | Single-dose vial | 65250-0266-20 |

When billing for EXPAREL, remember...

- 1 EXPAREL is approved for separate reimbursement in ambulatory surgery centers (ASC).
—See more important information about billing for EXPAREL inside
- 2 EXPAREL reimbursement is based on mg (ie, units) not vials or mL. Always make sure to bill units as the mg dosage.
- 3 EXPAREL is a local anesthetic that produces postsurgical analgesia. It is administered via single-dose infiltration. When infiltrated into the surgical site, it produces local analgesia. It may also be infiltrated in the fascial plane to produce regional analgesia as a regional field block. Regional anesthetic techniques to produce regional analgesia include, but are not limited to, transversus abdominis plane (TAP) block, pectoralis (PEC) and serratus plane blocks, erector spinae plane (ESP) block, thoraco-lumbar interfascial plane (TLIP) block, interspace between the popliteal artery and capsule of the posterior knee (iPACK), and quadratus lumborum (QL) block. EXPAREL may also be administered as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia in total shoulder arthroplasty (TSA) and rotator cuff repair (RCR) procedures.

*10-digit NDC numbers should always be converted into the appropriate 11-digit NDC numbers when billing for reimbursement.

Please see Important Safety Information inside.
Please refer to accompanying full Prescribing Information.

NON-OPIOID
EXPAREL[®]
(bupivacaine liposome injectable suspension)

C9290
BILLING GUIDANCE

BILL FOR EXPAREL WITH HCPCS CODE C9290

Effective January 1, 2019, EXPAREL is eligible for separate Medicare reimbursement in a Medicare-certified ambulatory surgery center (ASC) setting.

- Effective July 1, 2020, EXPAREL is priced at \$1.29/mg* and should be billed using Healthcare Common Procedure Coding System (HCPCS) code **C9290** and Revenue Code 0636. Based on the \$1.29/mg* pricing
 - For the 266 mg (20 mL) dose, the allowed[†] amount for reimbursement is \$343.14*
 - For the 133 mg (10 mL) dose, the allowed[†] amount for reimbursement is \$171.57*

Reminder: EXPAREL reimbursement is based on mg (ie, units) not vials or mL. Always make sure to bill units as the mg dosage.

- ✓ The surgeon must dictate the amount of EXPAREL mg used and any unused mg in the operative notes even when administered by anesthesia. The amount must be expressed in mg (ie, units)
- ✓ Medicare reimburses for EXPAREL in the 2 doses that are available: 266 mg (20 mL) and 133 mg (10 mL)
- ✓ Commercial payers that follow the 2019 Medicare payment methodology and policy are also expected to reimburse EXPAREL when billed with HCPCS code **C9290**. Check with your payer's Provider Network Representative to confirm
- ✓ Check your ASC contracts to verify the reimbursement amount if your commercial contract reimburses at a percentage of the Medicare payment rate. Contact your payer's Provider Network Representative to confirm
- ✓ In the event that your ASC successfully negotiates reimbursement for EXPAREL with any of its commercial payers, it is important that your insurance verification process is updated to include EXPAREL
- ✓ It is important to notify the surgeons, anesthesiologists, and their office staff by providing a list of payers and the applicable benefit plan that will reimburse EXPAREL in an ASC setting

Important information about billing for EXPAREL that can impact opportunities for payment and successful negotiations with commercial payers.

- When EXPAREL is used, document it in the operative note
- Always bill with HCPCS **C9290** whenever EXPAREL is used, unless it is contractually prohibited
 - Read your contracts to determine if there are any provisions that do not allow the ASC to bill for drugs and/or HCPCS **C9290**
 - There may be state-specific tax implications for the ASC if a non-contracted supply is billed. It is important for the ASC to determine their specific state regulations
- Notify the payer that you would like to pursue contractual options to include reimbursement for EXPAREL

Why bill for EXPAREL?

- It increases opportunities for payers to add EXPAREL to their approved ASC list and/or your contract
- Payers do not know EXPAREL was used or is in demand unless it is billed
- Payer contract policies sometimes include provisions that allow for a drug, such as EXPAREL, to be covered even if it is not included in the ASC fee schedule
- It demonstrates the added cost to the procedure, so that payers have the necessary information to substantiate the cost of EXPAREL
- The payer can see the types of procedures that benefit from EXPAREL, which increases the likelihood of success in securing reimbursement for EXPAREL

*Pricing is subject to Centers for Medicare & Medicaid Services (CMS) Medicare updates.

[†]The allowed amount for reimbursement is based on the full dose being used for the surgical procedure and is subject to CMS Medicare updates.

Indication

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Please refer to accompanying full Prescribing Information.

**For more information, please visit www.EXPAREL.com
or call 1-855-793-9727.**

NON-OPIOID
EXPAREL[®]
(bupivacaine liposome injectable suspension)

CAPTURE REIMBURSEMENT WHEN EXPAREL IS USED IN A SURGICAL CASE

For Medicare and commercial payers that require the CMS 1500 form or electronic 837P form, follow these steps:

STEP 1: DOCUMENTATION

- ✓ The amount of EXPAREL used in a surgery case is to be documented in the patient's medical record
- ✓ If any amount of EXPAREL is not used, known as *drug wastage*, it must also be documented in the medical record and indicated that the unused amount was discarded. EXPAREL drug wastage may be billed using the HCPCS modifier "JW" on a separate line of the form

STEP 2: BILLING FOR EXPAREL

- ✓ Bill for EXPAREL using HCPCS code **C9290**
- ✓ Document and bill the dosage as units (266 mg or 133 mg)
- ✓ Enter the number of units given in box 24G

| A. _____ | | B. _____ | | C. _____ | | D. _____ | | 23. PRIOR AUTHORIZATION NUMBER | | | | | | | | | | | |
|--|----|---------------------|----|---|----|--|------------|----------------------------------|-------|-----------------|------|------------------------|-----|-------------------|--|------------|--|----------------------------|--|
| E. _____ | | F. _____ | | G. _____ | | H. _____ | | | | | | | | | | | | | |
| I. _____ | | J. _____ | | K. _____ | | L. _____ | | | | | | | | | | | | | |
| 24. A. DATE(S) OF SERVICE | | B. PLACE OF SERVICE | | C. EMG | | D. PROCEDURES, SERVICES, OR SUPPLIES | | E. DIAGNOSIS | | F. \$ CHARGES | | G. DAYS OR UNITS | | H. PPDOT Form Per | | I. D. QUAL | | J. RENDERING PROVIDER ID # | |
| MM | DD | YY | MM | DD | YY | | CPTR/HCPCS | MODIFIER | POINT | | | | | | | | | | |
| 01 | 07 | 19 | 01 | 07 | 19 | 24 | | 63030 | | A | 8500 | 00 | 1 | | | | | | |
| 01 | 07 | 19 | 01 | 07 | 19 | 24 | | C9290 | | A | 262 | 50 | 200 | | | | | | |
| 01 | 07 | 19 | 01 | 07 | 19 | 24 | | C9290 | JW | A | 87 | 50 | 66 | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | |
| 25. FEDERAL TAX I.D. NUMBER | | SSN EIN | | 26. PATIENT'S ACCOUNT NO. | | 27. ACCEPT ASSIGNMENT? | | 28. TOTAL CHARGE | | 29. AMOUNT PAID | | 30. Rev'd for NUCC Use | | | | | | | |
| | | | | | | YES <input type="checkbox"/> NO <input type="checkbox"/> | | \$ | | \$ | | | | | | | | | |
| 31. SIGNATURE OF PHYSICIAN OR SUPPLIER | | | | 32. SERVICE FACILITY LOCATION INFORMATION | | | | 33. BILLING PROVIDER INFO & PH # | | | | | | | | | | | |
| INCLUDING DEGREES OR CREDENTIALS | | | | | | | | () | | | | | | | | | | | |
| (I certify that the statements on the reverse apply to this bill and are made a part thereof.) | | | | | | | | | | | | | | | | | | | |
| SIGNED | | DATE | | a. NPI | | b. NPI | | a. NPI | | b. NPI | | | | | | | | | |

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

STEP 3: BILLING FOR DRUG WASTAGE

- ✓ Drug amounts that are unused and discarded may be billed separately using the HCPCS modifier "JW"
- ✓ The modifier is noted as "**C9290 JW**" and is billed on a separate line. In order for the drug wastage to be reimbursed, providers must report 2 claim lines to represent both the used and unused amount of the drug

Check with your Provider Network Representative regarding the appropriate claim form and process to bill for EXPAREL if they do not use the CMS 1500 form or electronic 837P form.

Please see Important Safety Information inside.

Please refer to accompanying full Prescribing Information.

See more important information about billing for EXPAREL inside.

For reimbursement support or questions, please call 1-855-793-9727, email reimbursement@pacira.com, or visit www.EXPAREL.com/reimbursement.



©2020 Pacira BioSciences, Inc.
Parsippany, NJ 07054 PP-EX-US-5873 09/20

